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The major concerns with endocrine disruptors in the environment are based mostly on effects that
have been observed on the developing embryo and fetus. The focus of the present manuscript is
on disruption of three hormonal systems: estrogens, androgens, and thyroid hormones. These
three hormonal systems have been well characterized with regard to their roles in normal
development, and their actions during development are known to be perturbed by endocrine-
disrupting chemicals. During development, organs are especially sensitive to low concentrations of
the sex steroids and thyroid hormones. Changes induced by exposure to these hormones during
development are often irreversible, in contrast with the reversible changes induced by transient
hormone exposure in the adult. Although it is known that there are differences in embryonic/
fetal/neonatal versus adult endocrine responses, minimal experimental information is available to aid
in characterizing the risk of endocrine disruptors with regard to a number of issues. Issues
discussed here include the hypothesis of greater sensitivity of embryos/fetuses to endocrine
disruptors, irreversible consequences of exposure before maturation of homeostatic systems and
during periods of genetic imprinting, and quantitative information related to the shape of the
dose-response curve for specific developmental phenomena. Key words: androgen, development,
embryo, endocrine disruptors, estrogens, fetus, thyroid. - Environ Health Perspect 107(suppl 4):
613-618(1999).
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An endocrine disruptor has recently been
described as "an exogenous chemical sub-
stance or mixture that alters the structure or
function(s) of the endocrine system and
causes adverse effects at thelevel ofthe organ-
ism, its progeny, populations, or subpopula-
tions of organisms, based on scientific
principles, data, weight-of-evidence, and the
precautionary principle" (1). To address con-
cerns ofpotential effects ofendocrine disrup-
tors, the National Institute ofEnvironmental
Health Sciences and other co-sponsors held a
workshop to characterize the effects from
environmental exposures to endocrine dis-
ruptors on human health. The workshop
provided a forum to discuss methods and
data needed to improve risk assessments of
endocrine disruptors. This article is the
product ofone ofsix subgroups from that
workshop. It is based on the work group's
discussion ofa set ofquestions provided by
the organizing committee ofthe workshop.
The following is a list ofquestions posed to
the working group on endocrine function
during development that served as the basis
for the information discussed in this report.
* What should be included in a baseline
model to describe quantative relation-
ships among the processes controlling
normal development?
* How do perturbations at critical stages of
development lead to adverse effects, e.g.,
impaired reproductive function, neurologic
effects, cancer?
* Howcan these changes be quantified?
* By what mechanisms do endocrine dis-
ruptors perturb endocrine function dur-
ing development and alter risks from
normallevels ofendogenous hormones?
* What are the principal mechanisms by
which endocrine disruptors are thought to
act on thedeveloping reproductive tract?
* Are there effective repair mechanisms
operating during development to reduce
theeffects ofendocrinedisruptors?
* Are there adequate/relevant animal models
forevaluatingpotential human effects?
We focused on the regulatory processes of
normal development and on how exposure to
low doses (that is, doses encountered in the
environment) ofendocrine disruptors at criti-
cal stages ofdevelopment can lead to adverse
health effects. We also discussed areas where
information is needed to permit better evalu-
ation oftherisks ofendocrinedisruptors.
The authors feel that additional research in
five areas is essential: a) mechanisms ofnormal
development; b) differences ofendocrine dis-
ruptor effects between embryo/fetus/neonate
and adult; c) mechanisms ofendocrine disrup-
tion; d) dose-response assessment involving
examination over a wide range ofdoses, from
levels encountered in theenvironment through
doses that produce acute toxicity; and e) the
design ofscreens to accurately predict unique
developmental effects.
Mechanisms of Normal
Development
Basic information is needed on the normal
molecular, cellular, and physiologic develop-
mental mechanisms perturbed by altered
endocrine function during organogenesis
(2-4). Some ofthe resultant developmental
changes may not be detectable until later in
life (5). Also, knowledge acquired through the
study ofdevelopmental perturbation is likely
to lead to a better understanding ofnormal
processes occurringduringthattime in life.
Information is required for both humans
and other animals. Knowledge ofmechanisms
affected by endocrine perturbation due either
to congenital defects, induding experimental
gene knockout systems, or to application of
synthetic or naturally occurring endocrine-
mimickingcompoundswouldbe useful.
We recognize that development is
epigenetic, which refers to changes in gene
activityduringdevelopment that are mediated
by environmental (chemical) signals (6).
Autocrine, paracrine (such as growth factors),
and endocrine (such as steroid) signals coordi-
nate the direction ofdifferentiation oftissues
during critical periods in development. The
differentiation oforgans thus involves a com-
plex cascade ofsignals whose action is depen-
dent on being released at precise times and
within a specific dose range. Coordination of
these processes depends on the transcription
ofgenes coding for these signaling molecules
and their receptors at appropriate times and
appropriate rates (7-9).
In the field of endocrine disruption,
particular regulatoryemphasis has been placed
on processes or tissues affected by estrogens,
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androgens, and thyroid hormones, as well as
their antagonistic analogs. Organ systems
responsive to the sex steroids include the male
and female reproductive organs, the central
nervous system, and the immune system,
whereas thyroid hormone affects most tissues.
The work group focused only on these three
hormone groups. This decision was based on
the extensive literature that is available
regarding these developmentally important
signaling molecules. The current identifica-
tion ofparticular endocrine-disrupting chem-
icals as mimics or antagonists of the sex
steroid (estrogen and androgen) and thyroid
hormones, and their respective functions,
facilitates the work group's goal toward an
understanding ofthe mechanism ofaction of
these known endocrine disruptors.
Quantitative aspects of these three
components ofthe endocrine system must be
carefully considered to determine ifcertain
developmental events and tissues are particu-
larly sensitive to the test compounds. With
specific regard to the dose issue, a critical
question that remains to be resolved is
whether higher doses may actually inhibit
some responses that are stimulated by much
lower doses, causing what has been described
as an inverted U-shaped dose-response curve
(7). To understand this phenomenon, the
normal concentration range for hormones
being disrupted must be characterized with
regard to avarietyofresponses (Figure 1).
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Figure 1. An inverted-U (nonmonotonic) dose-response
function associated with an increase in total estrogenic
activity in the blood. As shown here, there is already a
response occurring atzero dose of exogenous estrogenic
endocrine disruptor, due to the presence of endogenous
estrogen that is circulating in blood at a concentration
above the threshold for the response [based on data in
Sheehan et al. (38)]. On the basis ofthe assumption of a
monotonic dose-response function, which may not be a
valid assumption for endocrine disruptors, the conclu-
sion would be that dose 1 represents a threshold dose
below which no effect occurs (the response is at the
control level), and lower doses are then not tested. The
labeling of dose 1 in this figure as the NOEL (no
observed effect level) on the basis of testing three high
doses is only valid if the dose-response function does
notform an inverted U. Similarily, the use ofthe NOELto
estimate an acceptable daily intake (ADI) dose would be
invalid ifthere were an inverted -U dose-response curve.
The figure is based on data for prostate weight in adult
male mice following exposure to differentdoses of estro-
genic chemicalsduring fetal life(7).
Examples ofadditional information needed
on normal development indude the effects on
a) spatial (9) and chronologic patterns of
expression of relevant nuclear receptors
(including isoforms) and ofgenes known to
integrate cellular processes ofdevelopment,
such as the homeobox genes Hox, Wnt, Pit-i,
Pou, etc., and b) hormone-synthesizing and
hormone-catabolizing enzymes after treatment
with hormone analogs or endocrine-disrupting
chemicals (4,8). Quantitative analyses ofsuch
responses should be stressed in an attempt to
allowformulation ofpredictive hypotheses.
Differences between the
Embryo/Fetus/Neonate
and Aduft
During the differentiation of reproductive
organs, hormones, growth factors, and other
endogenous chemical mediators regulate
gene expression and direct differentiation
(10). One marked difference between expo-
sure to endocrine disruptors during critical
periods in development versus during adult-
hood is the irreversibility of an effect during
development (9,11,12).
Evidence indicates that changes in concen-
trations ofandrogen and estrogen (two hor-
mones involved in differentiation of the
reproductive organs) result in permanent
changes in cell function. For example, the
higher circulating levels oftestosterone (by
2-3 ng/ml) in male mouse fetuses relative to
female fetuses result in the differentiation of
tissue in the cranial region ofthe urogenital
sinus into prostatic tissue as opposed to vagi-
nal tissue. Many other differences between
males and females are also mediated by this
small sex difference in testosterone (12). In
addition, a small increase in total circulating
estradiol (about 50 pg/ml) permanently
altered prostate size in mice (7). It is thus
plausible thatdisruption ofthe action ofestro-
gen or androgen during critical periods can
lead to permanent alterations in the develop-
ment ofreproductive organs and other tissues
with receptors for these hormones. Some of
these effects can be unique to the time during
development in which the hormonal alter-
ation occurred (11). This contrasts with cyclic
changes in hormones that occur normally in
adult females during the menstrual cycle that
do notproduce permanent effects.
Although development is a period of
change, there are regulatory processes involved
in developmental processes, such as changes in
plasma-binding proteins during pregnancy,
that alter bioavailability ofcirculating steroids
(13,14). However, the principle ofhomeo-
stasis, which implies a level of constancy, is
difficult to applyduringdevelopment.
Diczfalusy (15) initiated the concept of
the maternal-placental-fetal unit. It is now
accepted that pregnancy in mammals
represents the interaction ofthree endocrine
systems, all ofwhich are changing throughout
pregnancy. The vast differences in gestation
length, hormone production, and the degree
ofintimacy offetal-maternal blood supplies
represent important barriers to understanding
the complex interactions between these sys-
tems in one species on the basis ofinforma-
tion obtained in another. Little is known
concerning the regulation of protein and
steroid hormones by the placenta in most
species, and this lack ofinformation limits
predictions concerning the effects of
endocrine-disrupting chemicals on the func-
tioning ofthe maternal-fetal-placental unit.
What is known, however, is that regardless of
the species, outcomes of endocrine mani-
pulations in adults are not predictive of
endocrine changes in fetuses (11).
Mechanisms of Endocrine
Disruption
Numerous mechanisms ofendocrine function
have been disrupted by endocrine disruptors.
Consideration ofthese end points allows the
identification ofend point measures that
can be used in specific screens and tests. End
points for the three hormonal systems that are
the focus here are also the focus ofnew regula-
tions currently being developed by the U.S.
Environmental Protection Agency (U.S. EPA)
under congressional mandate and named the
Endocrine Disruptor Screening and Testing
Program (1). Examples ofend points include
the following.
Steroids (Estrogen/Androgen)
Receptor binding andfunction. This
includes both activation and inhibition and is
an important mechanism of endocrine
disruption (14,16).
Steroidsynthesis inhibition. This is a
well-known mechanism by which steroid
(estrogen/androgen) hormone systems are
disrupted (17).
Plasma transportandrateofmetabolism
andckarance. An example is the free concen-
tration ofsteroid (not bound to plasma-bind-
ing proteins) in blood, which changes
dramatically between development and adult-
hood in rodents (18). Differences between
endogenous steroids and endocrine disruptors
in binding to plasma-binding proteins can dra-
matically alter the potency ofendocrine dis-
ruptors compared to the hormone, such as
estradiol, being mimicked by the endocrine
disruptor (19). Endocrine disruptors may
require metabolic activation in order to inter-
actwith one ofthese mechanisms (16).
Thyroid
Receptor binding andfunction. Currently
there are no reports ofxenobiotics binding to
the thyroid hormone receptor.
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Synthesis inhibitors. Several classes of
endocrine disruptors fall into this category,
including compounds that block thyro-
peroxidase (TPO), iodide uptake, and the
deiodinases (20).
Plasma transport and rate ofmetabo-
lism and clearance. Thyroid hormone must
be carried through the blood on serum pro-
teins. Some endocrine-disrupting chemicals
(polychlorinated biphenyls and dioxin)
inhibit thyroid hormone binding to plasma
transport proteins, resulting in more rapid
clearance and reduced thyroid hormone
levels (21).
Several types of endogenous hormones
and endocrine disruptors have been found
that interact with more than one component
ofthe endocrine system. An example involves
compounds, such as genistein in soy, that are
weak estrogens but that also block TPO (20).
Another example is that at a higher than
physiologic concentration, estradiol binds to
androgen receptors (22). Similarly, some
estrogenic endocrine disruptors, such as the
bis-hydroxy metabolite of the insecticide
methoxychlor, also bind to the androgen
receptor (23,24). Endocrine disruptors that
bind to steroid receptors such as p,p'-DDE
(the persistent in vivo metabolite ofthe insec-
ticide DDT) thus show the highest affinity
for one steroid receptor (in this case, andro-
gen receptors) but also show a lower binding
affinity for other receptors (estrogen recep-
tors) (25,26). As the dose ofp,p'-DDE or
methoxychlor increases, theywill thus bind to
multiple receptors. As a result, the change in
some end point to increasing doses of an
endocrine disruptor may reflect its action on
different components of the endocrine sys-
tem, and each componeni may contribute to
a composite dose response. For this reason,
the response to a dose on the high end ofthe
dose-response curve may be qualitatively dif-
ferent from and may not be a reliable predic-
torofthe response at much lower doses.
Endocrine disruptors that act to disrupt
the estrogen, androgen, and thyroid systems
have been the focus ofthe design ofscreens
and tests for detecting potential endocrine-
disrupting chemicals (25,27,28). However,
we know that these mechanisms do not repre-
sent the full range ofpotential endocrine dis-
ruption. Therefore, it is essential to recognize
that endocrine disruptors may interfere with
hormone actions in ways that would not be
identified in the assays currently contained in
the new U.S. EPA testing program (1).
Moreover, there are many potential mecha-
nisms by which endocrine disruptors could
produce nonlinear dose-response curves (29).
Dose-Response Assessment
The dose issue refers to the application ofthe
previous concepts to characterize the full
spectrum of the dose-response curve for
endocrine disruptors. The issues are as
follows: first, are current risk assessment pro-
cedures adequately evaluating the adverse
effects ofendocrine disruptors by examining
only a few doses that may be millions oftimes
higher than those typical of exposure by
human or wildlife? Second, there has been
considerable interest in the shape ofdose-
response curves for endocrine disruptors that
bind to intracellular receptors for endogenous
steroid hormones. However, until now, the
establishment ofthe dose range in toxicologic
studies on these chemicals has not been based
on an estimation ofwhether the doses admin-
istered would result in doses within target tis-
sues that would be below or above levels that
would saturate available receptors for the
endogenous hormone(s) being mimicked or
antagonized. In a multigenerational study in
which adults are administered a chemical
before and during the production of off-
spring, and then the offspring continue to be
dosed after weaning (the procedure is then
repeated for two generations), three doses are
usually examined (30). The lowest dose in
these experiments is typically a maximum of
50-fold below the highest dose. The highest
dose used in toxicologic experiments is based
on some index of acute toxicity, such as a
decrease in body weight without other signs
ofovert toxicity.
With regard to the shape of the dose-
response curve at low levels for endocrine dis-
ruptors that interact reversibly with hormone
receptors (and other regulatory macromole-
cules such as enzymes), consideration should
be given to characterizing the dose-response
curve within the predicted dose range for
regulating receptor activity on the basis ofthe
relative potency of the endocrine disruptor
and the endogenous hormone it mimics.
Third, the issue ofthe type ofhealth risk
posed by endocrine disruptors has generated
much discussion. There is evidence that
endocrine disruptors pose risks to functional
end points, such as neuromuscular and
behavioral changes (21,31,32), and organ
function (5,7,33). On the basis ofthese find-
ings, the U.S. EPA will now require tests for
endocrine disruptors that focus on adverse
effects on organ function (1).
Traditional approaches to determine
deleterious effects on the developing fetus
focused on high doses ofcompounds that may
cause fetal death, malformations, or complete
loss offunction (such as infertility) (34,35).
Tests commonly employed include classical
teratology tests. Such tests are referred to in
the industry as Segment 2 studies in which
gross malformations or death are the end
points.These studies involve administration
ofa chemical for a short period in pregnancy.
Multigenerational studies have been conducted
for relatively few of the chemicals that
will be screened by the U.S. EPA for
endocrine-disrupting activity (36). Whether
multigenerational studies conducted with a
few high doses will detect effects similar to
those seen with much lower doses is currently
being investigated for a few endocrine-dis-
rupting chemicals in studies being conducted
by the National Toxicology Program within
the National Institute of Environmental
Health Sciences.
Data for the mechanism ofaction ofthe
endocrine disruptor in question provide a
basis for predicting the types ofadverse effects
that may occur. However, these types ofdata
have not been available for most multigenera-
tional studies that have been conducted, or if
known, were not applied in the determina-
tion ofdoses to be examined [for contrasting
approaches in examining a chemical used in
plastic, bisphenol A (14,34)]. At present, lim-
iting factors in using multigenerational
studies to determine adverse developmental
effects include the time required to complete
these studies, interpretation of the extensive
amount ofdata generated, and cost effective-
ness of such studies with respect to the
knowledge gained about the effects. An
increase in the number ofdoses used in these
studies would increase costs unless accompa-
nied by the use ofsmaller numbers ofanimals
per group. A resolution of these complex
issues will require more information than is
now available.
The limitations of traditional teratologic
and multigenerational studies led the working
group to suggest the following research needs:
first, relevant and sensitive quantitative end
points must be identified and tested over a
much wider range ofdoses than have previ-
ously been examined. Second, the design of
these experiments should require knowledge
ofthe variability ofthe end points in the con-
trol population to adequately assess the num-
bers ofanimals that should be examined (i.e.,
conduct statistical power analysis). Third, the
shape of the dose-response curve for specific
responses should be determined with respect
to endocrine disruptors within a particular
class (for example, endocrine disruptors that
bind to estrogen receptors and show full ago-
nistic activity). Fourth, the mechanisms of
receptor binding and activation (and other
mechanisms) should be determined over the
full range ofdose responses. And finally, new
strategies and models for dose-response
assessment should be developed as data
become available.
In toxicologic studies, the current model
for endocrine disruptors is based on the
hypothesis that a) as dose increases, response
will increase or stay the same (a monotonic
dose-response curve is assumed), and b) a
threshold exists below which there is no
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increase in risk (relative to controls) due to
exposure (37). These assumptions, which are
based on studies conducted with high doses
of chemicals, have been challenged by the
results ofexperiments involving low doses of
endogenous hormones and endocrine
disruptors (7,14,29,38).
There are currently only a few ongoing
studies, including multigenerational studies,
that have been designed to address some of
these modeling needs and questions. By
addressing these issues, information will be
provided concerning the need to expand the
dose range for some chemicals. It will be
important to determine which properties of
chemicals might predict whether their
dose-response relationships will behave in a
complex fashion. Finally, regulatory agencies
will have to assess the impact that this infor-
mation will have on regulatory policies that
drive the design oftoxicologic studies (1).
Ability ofScreensto Predict
Embryonic Effects
Current hazard identification (for example,
identification ofwhether a chemical is an
endocrine disruptor) and, more generally, risk
assessment paradigms need to be reevaluated
to determine their effectiveness at assessing
effects oflow doses ofpotential endocrine dis-
ruptors on the developing organism. Although
screening systems can be designed to identify
endocrine-disrupting chemicals that elicit
effects at low doses, an additional concern is
whether there are unique effects ofexposure to
these endocrine disruptors during critical peri-
ods ofdevelopment (i.e., organogenesis). The
concern is that effects caused by exposure to
endocrine disruptors during critical periods in
development may not be predicted by studies
conducted at later times in life (after weaning)
and also may not be detected by in vitro
screens. There are data that support this possi-
bility (5,17,24,39-411). Additionally, the iden-
tification ofwhich end points in which tissues
should be evaluated for unique effects due to
exposure during development needs to be
morecarefully examined.
Proposed Chemicalsto
Addressthe Issue of Dose in
Testsfor Endocrine Disruptors
Considerably more empirical data are needed
that directly compare the high end of the
dose-response curve with the low end. To
address this issue, the work group suggested
the following compounds for initial evalua-
tion: diethylstilbestrol (DES), methoxychlor,
bisphenol A, octylphenol, phthalates, keto-
conazole, flutamide, propylthiouracil (PTU),
and genistein. These compounds are pro-
posed because much is already known about
their effects and mechanisms ofaction and
because they present different spectra of
effects and mechanisms. Specifically, DES is a
potent ligand for the estrogen receptor (ER).
Methoxychlor has both estrogenic and
antiandrogenic effects and must be metabo-
lized to be active (24). Bisphenol A is an
estrogenic chemical that binds to the ERwith
modest affinity (14) and has been reported to
result in prostate enlargement and other
changes in the reproductive system in mice
(42) and changes in pituitary function in rats
(43). Octylphenol also binds to the ERand is
estrogenic in in vitro and in vivo assay systems
(44) but shows significantly different binding
to plasma steroid-binding proteins than
bisphenol A (14). Some phthalates, such as
dibutyl phthalate, show evidence of non-
receptor-related effects on the androgen sys-
tem (17). Ketoconazole blocks androgen
synthesis and thus is antiandrogenic by a
receptor-independent mechanism (17).
Flutamide is a relatively pure androgen
receptor blocker and provides a positive con-
trol antiandrogen (25). PTU produces thy-
roid effects by inhibiting thyroid hormone
synthesis (45). Genistein has many actions,
among which are binding to and activation of
the ER as well as tyrosine kinase inhibition
(19, 46). Thus, while a common thread of
hormone-related activities runs through this
group ofchemicals, they present a sufficient
spectrum ofeffects to allow a more broad
assessment of the possibility of low-dose
effects and qualitative differences in response
across the dose-response curve associated with
nonmonotonic functions.
The doses used for these in vivo studies
should cover the dose ranges from just below
overtly toxic (using the current method of
high dose selection) to approximately 6
orders ofmagnitude lower. This dose range
should be sufficient to provide some informa-
tion on the likelihood of nonmonotonic
dose-response functions.
Although the end points measured in
these studies should be relevant to the com-
pound being tested, whenever possible, an
attempt to link end points to currently
accepted indices oftoxicity should be made.
At least some of the end points measured
should take advantage of what is known
about the molecular effects and mechanisms
ofeach compound (i.e., levels ofhormones
being mimicked, receptor number and action
in specific target tissues), whereas others
should be more organ-level and whole-ani-
mal-level end points (i.e., development ofthe
reproductive or thyroid systems, gamete
numbers, or rate ofgrowth). The purpose of
examining more sensitive end points for each
compound against the more traditional end
points in toxicologic studies is to establish
whether an effect is adverse by traditional cri-
teria. However, it is also recognized that part
ofthe new paradigm that has been developed
by the U.S. EPA in its endocrine disruptor
screening and testing program is a focus on a
different set of outcomes from those previ-
ously used in most toxicologic studies (1).
The development of this database will
provide important information regarding the
prevalence of nonmonotonic dose-response
curves and unique low-dose effects. As this
information becomes available, it can be
decided ifcurrent dose-response assessment,
hazard identification, and risk assessment par-
adigms need to be further modified. This will
be possible, as the endocrine disruptor screen-
ing and testing program is designed to be a
process that can be modified as new informa-
tion becomes available [1). Future decisions
must be based on data, not on presumption
and extrapolation.
The question of whether mixtures of
compounds have a profile of toxicity that
differs qualitatively from that of its compo-
nents has also been a concern with regard to
endocrine disruptors. This question is ofspe-
cial importance given new regulatory man-
dates (i.e., Food Quality Protection Act) to
carry out risk assessments based on the accu-
mulated exposures to agents that exert their
toxicity by a common mechanism. In prac-
tice, the default approach to cumulative risk
assessments is to consider the effects ofindi-
vidual components to be additive if they
induce similar effects and there is no contra-
dictory evidence to suggest a nonadditive
interaction. However, if the dose-response
relationships are complex and nonlinear for
the components, then this practice would not
be appropriate. This issue must be addressed,
particularly if it is determined that endocrine
disruptors have complex, nonmonotonic
dose-response relationships.
Prostate Development as an
Example of an Endocrine-
Mediated Process Subject
to Endocrine Disruption
Prostate development in the male mouse serves
as a good example ofthe potential seriousness
ofendocrine disruptors for the developing
fetus. The prostate gland develops from the
urogenital sinus (UGS) under the influence of
androgens. In the day-14 male mouse embryo,
testicular testosterone secretion increases, but
testosterone must be converted to 5a-dihy-
droxytestosterone (DHT) by 5a-reductase for
normal prostate development to occur. DHT
stimulates androgen receptor-positive mes-
enchyme cells to induce glandular epithelial
budding. Thus, the critical parameters for
modeling are fetal circulating testosterone
levels, UGS mesenchymal 5a-reductase activ-
ity, androgen receptor content ofUGS mes-
enchyme, and mass ofUGS mesenchyme at
the time ofinitial prostateorganogenesis (10).
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With regard to the measurement of
estradiol and testosterone in plasma, the total
concentration in plasma can be misleading.
In rodents, the concentration of estrogen
binding plasma proteins (alphafetoprotein)
that modify uptake into tissues is dramatically
higher in fetuses than adults. As a result, the
free (unbound to plasma proteins) concentra-
tion of estradiol is approximately 10-fold
lower in fetuses than in adults (18). This is
important because endocrine-disrupting
chemcials show significant differences in bind-
ing to these plasma proteins relative to estra-
diol, and thus show substantially different
uptake into fetal tissues than predicted by in
vitro assays that do not take this into account
in assessing the potency of these chemicals
(19). In sharp contrast, the levels of free
testosterone are quite high in fetuses, as
rodents do not have a high-affinity plasma-
binding protein for testosterone (47).
A small increase in circulating estradiol
in male fetuses permanently increases adult
prostate weight via an increase in gland gen-
esis (7). Specifically, a 50% increase in cir-
culating estradiol led to a 40% increase in
the number of prostatic epithelial buds at
the end ofthe first day ofprostate differenti-
ation. Fetal testosterone levels were not
increased by estradiol treatment, but prosta-
tic androgen receptors were permanently
increased (7). However, whether UGS 5a-
reductase activity was influenced by estradiol
treatment and whether there was any change
in the mass ofunderlying UGS mesenchyme
has not been examined. Quantitative analy-
ses of these additional parameters would
assist in formulating predictive hypotheses.
The relevance of the prostate model to
the assessment ofendocrine-disrupting com-
ponds is that it provides an example of an
organ that has been extensively studied with
regard to the impact ofalteration in enzyme
activity (50c-reductase) and circulating
steroid levels (namely, testosterone and
estradiol). Levels of these steroids can be
added to or interfered with by endocrine
disruptors that bind to their receptors and
act as mimics or antagonists, respectively.
Alternatively, circulating levels of these
steroids could be altered by disruption of
synthesis ofor by competition for binding to
plasma steroid-binding proteins. The impor-
tance of the interaction of mesenchyme and
epithelium in the UGS has been studied in
great detail, and there are data on the
ontogeny of steroid receptors (4,48,49). A
detailed understanding ofthe mechanisms of
development is required to fully understand
the mechanisms of endocrine disruption,
particularly with regard to understanding in
molecular detail the possibility that low
doses of a particular chemical might interfere
with normal developmental processes (30).
Conclusions
Much of the controversy surrounding the
problem ofendocrine disruptors in the envi-
ronment is related to potential effects on the
embryo and fetus. This working group deter-
mined that we have limited information on
both the normal role of the hormones in
development and on potential endocrine dis-
ruptors. Multigenerational assays have been
the only means ofassessing the potential for
disrupting normal development by endocrine-
disrupting chemicals. The principal conclu-
sion is that there is a need for more basic
information about hormonal involvement in
development and for new methods to assess a
variety ofcompounds for endocrine disrup-
tor activity, particularly during critical
periods in organogenesis.
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